Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBLGNASDAQ:INBSNASDAQ:NURONASDAQ:POAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBLGBone Biologics$0.66-3.0%$0.80$0.57▼$4.25$2.16M0.531.39 million shs9,465 shsINBSIntelligent Bio Solutions$1.28-0.8%$1.71$1.00▼$3.04$8.72M4.63547,789 shs39,804 shsNURONeuroMetrix$4.39+1.0%$4.40$2.66▼$4.73$9.03M1.8215,397 shs2,340 shsPOAIPredictive Oncology$1.06$1.19$0.55▼$3.06$9.47M1.112.35 million shs62,532 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBLGBone Biologics0.00%+0.01%-17.06%-31.10%-55.55%INBSIntelligent Bio Solutions0.00%+8.40%-14.57%-8.51%-52.04%NURONeuroMetrix0.00%-1.45%-2.03%+3.09%-2.25%POAIPredictive Oncology0.00%+13.31%-26.90%-23.74%-29.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBLGBone Biologics0.9147 of 5 stars0.02.00.00.03.80.01.3INBSIntelligent Bio Solutions0.3039 of 5 stars0.02.00.00.02.00.00.6NURONeuroMetrix0.4206 of 5 stars0.03.00.00.01.80.00.6POAIPredictive Oncology2.8468 of 5 stars3.05.00.00.03.60.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBLGBone Biologics 0.00N/AN/AN/AINBSIntelligent Bio Solutions 0.00N/AN/AN/ANURONeuroMetrix 0.00N/AN/AN/APOAIPredictive Oncology 2.00Hold$3.00183.02% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBLGBone BiologicsN/AN/AN/AN/A$7.42 per shareN/AINBSIntelligent Bio Solutions$3.03M2.88N/AN/A$0.80 per share1.60NURONeuroMetrix$3.03M2.98N/AN/A$13.18 per share0.33POAIPredictive Oncology$1.62M5.83N/AN/A$2.04 per share0.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBLGBone Biologics-$8.95MN/A0.00N/AN/AN/A-124.71%-111.64%5/13/2025 (Estimated)INBSIntelligent Bio Solutions-$10.16MN/A0.003.66N/A-323.79%-146.03%-83.62%5/14/2025 (Estimated)NURONeuroMetrix-$6.53M-$4.59N/A∞N/A-203.71%-42.56%-39.26%5/21/2025 (Estimated)POAIPredictive Oncology-$13.98M-$3.05N/AN/AN/A-1,012.32%-286.30%-122.11%5/13/2025 (Estimated)Latest BBLG, NURO, POAI, and INBS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025POAIPredictive Oncology-$0.09N/AN/AN/A$1.50 millionN/A2/13/2025Q2 2025INBSIntelligent Bio SolutionsN/A-$0.50N/A-$0.50N/A$610.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBLGBone BiologicsN/AN/AN/AN/AN/AINBSIntelligent Bio SolutionsN/AN/AN/AN/AN/ANURONeuroMetrixN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBLGBone BiologicsN/A14.8914.89INBSIntelligent Bio SolutionsN/A0.920.76NURONeuroMetrixN/A13.8812.70POAIPredictive OncologyN/A1.201.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBLGBone Biologics34.30%INBSIntelligent Bio Solutions32.97%NURONeuroMetrix19.40%POAIPredictive Oncology9.04%Insider OwnershipCompanyInsider OwnershipBBLGBone Biologics7.50%INBSIntelligent Bio Solutions0.28%NURONeuroMetrix7.30%POAIPredictive Oncology3.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBLGBone Biologics23.27 million2.31 millionNot OptionableINBSIntelligent Bio Solutions106.81 million5.26 millionNot OptionableNURONeuroMetrix202.06 million1.90 millionNot OptionablePOAIPredictive Oncology308.93 million6.44 millionNot OptionableBBLG, NURO, POAI, and INBS HeadlinesRecent News About These CompaniesPredictive Oncology develops new approach to identifying viable abandoned drugsApril 16, 2025 | markets.businessinsider.comRenovaro says Predictive Oncology terminated merger agreementApril 5, 2025 | markets.businessinsider.comPredictive Oncology Stock Price, Quotes and ForecastsApril 2, 2025 | benzinga.comPredictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate UpdateApril 1, 2025 | globenewswire.comPredictive Oncology (POAI) Uses AI to Slash Drug Discovery Timelines & Boost Cancer ResearchMarch 27, 2025 | insidermonkey.comPredictive Oncology (POAI) Uses AI to Slash Drug Discovery Timelines & Boost Cancer ResearchMarch 27, 2025 | msn.comTop 8 AI News Updates Driving Markets TodayMarch 25, 2025 | insidermonkey.comPredictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and OvaryMarch 25, 2025 | globenewswire.comPredictive Oncology completes sale of Skyline Medical assets to DeRoyalMarch 21, 2025 | markets.businessinsider.comPredictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries to Focus on AI-Driven Drug DiscoveryMarch 20, 2025 | quiverquant.comPredictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal IndustriesMarch 20, 2025 | globenewswire.comPredictive Oncology moves to finalize merger agreement with RenovaroMarch 3, 2025 | markets.businessinsider.comRenovaro completes first milestone payment for Predictive Oncology dealMarch 3, 2025 | markets.businessinsider.comPredictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro BiosciencesMarch 3, 2025 | finance.yahoo.comPredictive Oncology Inc. Completes Registered Direct Offering of 363,336 Shares at $1.50 Per ShareFebruary 19, 2025 | quiverquant.comPredictive Oncology Closes Registered Direct OfferingFebruary 19, 2025 | globenewswire.comPredictive Oncology prices 363,336 shares at $1.50 in registered direct offeringFebruary 19, 2025 | markets.businessinsider.comPredictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 19, 2025 | finance.yahoo.comPredictive Oncology (POAI) Struggles AI-Driven Drug Repurposing BreakthroughFebruary 18, 2025 | msn.comPredictive Oncology Inc.: Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug RepurposingFebruary 18, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBLG, NURO, POAI, and INBS Company DescriptionsBone Biologics NASDAQ:BBLG$0.66 -0.02 (-2.96%) Closing price 03:58 PM EasternExtended Trading$0.66 -0.01 (-0.76%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.Intelligent Bio Solutions NASDAQ:INBS$1.28 -0.01 (-0.78%) Closing price 03:59 PM EasternExtended Trading$1.26 -0.02 (-1.17%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.NeuroMetrix NASDAQ:NURO$4.38 +0.05 (+1.04%) Closing price 03:58 PM EasternExtended Trading$4.41 +0.03 (+0.57%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.Predictive Oncology NASDAQ:POAI$1.06 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
